Lung Cancer | Specialty

Upfront Use of Immunotherapy for NCSLC

February 20th 2017

Third-Generation ALK Inhibitors for NSCLC

February 20th 2017

Upfront Use of Next-Generation ALK Inhibitors in NSCLC

February 20th 2017

Progression of ALK+ NSCLC

February 20th 2017

Upfront Use of Osimertinib in EGFR+ NSCLC

February 20th 2017

Osimertinib for EGFR T790M Resistance Mutations in NSCLC

February 20th 2017

Relapsed or Refractory EGFR+ NSCLC

February 20th 2017

Addition of Bevacizumab to Up-front therapy for EGFR+ NSCLC

February 20th 2017

Treatment for EGFR+ NSCLC

February 20th 2017

EGFR Testing for NSCLC

February 20th 2017

Molecular Testing for NSCLC in 2017

February 20th 2017

Immunotherapy, Molecular Testing Propel Dramatic Changes in Lung Cancer Care

February 16th 2017

2017 is poised to be another pivotal year in non–small cell lung cancer, given the exciting advances in the field at the end of last year.

Rovalpituzumab Tesirine Active and Safe in Small Cell Lung Cancer

February 13th 2017

Rovalpituzumab tesirine demonstrated encouraging single-agent antitumor activity with a manageable safety profile in the treatment of patients with recurrent small cell lung cancer.

Dr. Levine on Simulation in the Management of EGFR-Mutated Advanced NSCLC

February 11th 2017

Stacie Levine, MD, associate professor of Medicine, Director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, The University of Chicago Medicine, discusses a trial regarding simulation in the management of EGFR-mutated advanced NSCLC

Dr. Neal on Ongoing Trials of Immunotherapy for Lung Cancer

February 11th 2017

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses ongoing trials in immunotherapy for patients with lung cancer.

Dr. Mutti on Current Role of Immunotherapy for Mesothelioma

February 9th 2017

Luciano Mutti, MD, professor of Cancer Research, University of Salford Manchester, discusses the current role of immunotherapy for patients with mesothelioma.

Dr. Drilon on RET Rearrangements in NSCLC

February 8th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses RET rearrangements for patients with non–small cell lung cancer (NSCLC).

Dr. Socinski on Recent Setbacks in Immunotherapy Combinations in NSCLC

February 7th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses recent setbacks in immunotherapy combinations in non–small cell lung cancer (NSCLC).

Dr. Chiang on Immunotherapy in Patient Populations for Lung Cancer

February 7th 2017

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses immunotherapy in specific patient populations with lung cancer.

Expert Explains Efforts to Optimize EGFR TKIs in NSCLC

February 6th 2017

H. Jack West, MD, discusses the benefits of EGFR tyrosine kinase inhibitors in non–small cell lung cancer, challenges with determining optimal sequencing, and potential combinations on the horizon.